A flying START for carers of people with dementia  by Banerjee, Sube
Comment
www.thelancet.com/psychiatry   Vol 1   December 2014 489
disaster relief, also face deployments. Similar questions 
await about cumulative deployment length in these 
groups, and number of deployments per given time, 
as policy is created for care providers deploying, for 
example, to restore infrastructure after a tsunami or to 
stop the spread of Ebola.
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A ﬂ ying START for carers of people with dementia
The data from the START trial by Gill Livingston and 
colleagues1 published in this issue of Lancet Psychiatry 
show enduring beneﬁ ts for carers from a psychological 
intervention for family carers of people with dementia. 
These strong and important ﬁ ndings show that a 
brief, 8-session, individual intervention given early in 
contact with services, not only works in the short term 
(8 months), but also in the long term (24 months), in 
terms of clinical and cost-eﬀ ectiveness.  
This well conducted study addresses an important 
area for intervention for which the evidence base 
is sparse. Family carers are a vital resource for the 
management of people with dementia. Their wellbeing 
and ability to care can be compromised by the anxiety 
and depression that all too often are consequences of 
taking on the onerous duties of caring for a relative with 
dementia. The National Dementia Strategy2 identiﬁ es 
family carers as “the most valuable resource for people 
with dementia”. More than 600 000 family members 
provide £8 billion per year of unpaid dementia care in 
the UK.3 Family carers are a crucial determinant of quality 
of life and positive outcomes for people with dementia, 
and having a coresident carer exerts a 20-fold protective 
eﬀ ect against the risk of institutionalisation.4 Carers 
are pivotal in provision of direct help and accessing of 
formal support; two-thirds of people with dementia 
live in the community, and for them family members 
are the most important source of care.5 Caregiving 
extends beyond hands-on care to include the planning 
of future support needs, monitoring and supervision, 
preservation of the patient’s sense of self, and helping 
them to develop new and valued roles.6
Caregiving presents substantial challenges, and half 
of all people with dementia in the community receive 
at least 35 h of informal care per week.7 Many carers 
of people with dementia are older themselves, and 
are physically frail with health disorders of their own. 
Dementia is a progressive and terminal disorder and 
caregiving is not a ﬁ xed set of experiences, but evolves 
in “caregiving career”.8 The main responsibilities for 
day-to-day care tend to fall to one family member, 
usually a woman (with the order of likelihood being 
spouse, daughter, daughter-in-law, son, other relative, 
and non-relative). Although many carers derive 
personal satisfaction from caring, the experience can 
also be detrimental—physically, psychologically, and 
ﬁ nancially.3,9 Dementia caregivers have more anxiety, 
stress, and depression than non-caregivers, and caring 
for patients with dementia has more negative eﬀ ects 
than caring for patients with other disorders10,11—
depression occurs in a third of dementia carers.12 
Therefore, any intervention that reduces the risk of such 
negative outcomes for carers should be of welcome 
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START therapy has a strong theoretical basis. It is an 
individual therapy, and therefore can be given to carers 
in their own homes or in other settings without the 
organisational complexities that come from group 
approaches. It is designed to be given by non-clinically 
trained psychology graduates who are a readily available 
and low-cost workforce compared with scarce clinical 
staﬀ  or highly trained clinical psychologists. START 
is a straightforward, manualised, evidence-based 
intervention for which training is available, which is 
clinically and cost-eﬀ ective, and free to use. It both 
prevents and treats mental disorders in carers in the 
short and long term.  
On the basis of these results, the START intervention 
should be oﬀ ered as individual therapy to all family 
carers of people with dementia as part of the support 
with a timely diagnosis. START should be a speciﬁ ed 
component of the diagnostic services for dementia 
(such as memory services) that are commissioned by 
Clinical Commissioning Groups throughout the UK. It 
should not be possible for a service or commissioner 
to consider themselves good, unless they provide such 
therapy to carers.
Without the work of family carers, the formal care 
system would collapse. Government policy supports 
family carers for people with dementia via its Carers’ 
Strategy and the National Dementia Strategy,13 
but sometimes what is actually being done by 
commissioners and services to help them is unclear. 
Clarity is absent in policy and service speciﬁ cations 
about what carers can and should expect from services 
for people with dementia and their carers, which vary 
widely across the UK. This variation has been driven 
partly by localism in service commissioning, but also by 
local commissioners and service providers having not 
had evidence for what good carer support looks like. 
The Article by Livingston and colleagues should change 
that.
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Psychotropic drugs in low-income countries
More than 150 countries, mainly in low-income regions, 
adopt the WHO model for public sector funding of 
medicines, including the use of an essential medicines 
list.1 By contrast with this list’s ethos of rational, 
cost-eﬀ ective pharmacotherapy, no coherent policy 
governs availability of pharmaceuticals in the private 
sector. Inconsistency in policies has led to substantial 
diﬀ erences in drug availability in low-income regions, 
with few options for patients dependent on public 
sector health care. This disparity is aggravated by 
inconsistency in the availability of essential medications 
in public facilities, either because of a poor health-care 
infrastructure, corruption, or ﬁ nancial constraints; this 
pervasive problem results in many patients having no 
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